The historical rank and industry rank for Neuland Laboratories's Pretax Margin % or its related term are showing as below:
NSE:NEULANDLAB'
s Pretax Margin % Range Over the Past 10 Years
Min: 2.73 Med: 11.68 Max: 26.49
Current: 24.17
NSE:NEULANDLAB's Pretax Margin % is ranked better than 86.7% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs NSE:NEULANDLAB: 24.17
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Neuland Laboratories Pretax Margin % Related Terms
Neuland Laboratories Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a Pretax Margin % of 37.04% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Neuland Laboratories and its competitors. This is 217% above median its historical median of 11.68. Over the past decade, Neuland Laboratories' Pretax Margin % has ranged from 2.73 to 26.49. According to the industry distribution chart, Neuland Laboratories ranks #127 out of 955 companies in the Drug Manufacturers industry, placing it in the top 13.3%.
Is Neuland Laboratories' Pretax Margin % too high?
Neuland Laboratories' current Pretax Margin % of 37.04% is 217% above median its 10-year median of 11.68. Over the past 10 years, this metric has ranged from a low of 2.73 to a high of 26.49. The Drug Manufacturers industry median Pretax Margin % is 7.28. Neuland Laboratories' value of 37.04% is 408.8% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #127 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #127 out of 955 companies for Pretax Margin %. This places Neuland Laboratories in the top 13% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Neuland Laboratories' value of 37.04% is 408.8% above this benchmark. Historically, Neuland Laboratories' own Pretax Margin % has ranged from 2.73 to 26.49 over the past decade. While the company's 10-year median is 11.68 vs. the industry median of 7.28, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Pretax Margin % of 37.04% is 408.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Pretax Margin % is 37.04%, which is 217% above median its own 10-year median of 11.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,471.48, compared to a current price of ₹17,961.00 — trading 9% above its estimated fair value. The current Pretax Margin % is 37.04%, which is 217% above median its 10-year median of 11.68 and 408.8% above the Drug Manufacturers industry median of 7.28. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Pretax Margin % is 37.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹17,961.00 is trading 9% above its estimated GF Value™ of ₹16,471.48.
GuruFocus considers Neuland Laboratories to be Fairly Valued.
Key valuation signals for NSE:NEULANDLAB:
Pretax Margin %: 37.04% (217% above median its 10-year median of 11.68)
GF Value™: ₹16,471.48 vs. price of ₹17,961.00 (9% above fair value)
Industry Position: 408.8% above the Drug Manufacturers median (#127 of 955)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
